 |
Medical Crossfire: Hot Topics in Hypercholesterolemia: Impact of Recent Clinical Trial Data on Clinical Practice CME Michael H. Davidson, MD, FACC, FACP; Peter H. Jones, MD; Daniel J. Rader, MD Author Information and Disclosures Release Date: May 29, 2008; Valid for credit through May 29, 2009 | Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity, "Medical Crossfire: Hot Topics in Hypercholesterolemia: Impact of Recent Clinical Trial Data on Clinical Practice," was designed for release on Medscape.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Temple University |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - State why LDL remains the primary goal of lipid-lowering therapy.
- Describe the possible merits of other intermediary or surrogate markers (eg, carotid intimal
media thickness, C-reactive protein, and other markers of lipid values such as HDL).
- Develop an evidence-based strategy for reducing CV risk in patients with hypercholesterolemia to achieve recommended treatment goals.
Author Disclosures Michael H. Davidson, MD, FACC,
FACP
Disclosure: Grant/Research Support: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer Laboratories, Roche Pharmaceuticals, Takeda Pharmaceutical Company; Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Pfizer Laboratories, Roche Pharmaceuticals, sanofi-aventis U.S. LLC, Synarc,
Takeda Pharmaceutical Company; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals, Daiichi-Sankyo, Inc., diaDexus, Inc., Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer Laboratories, Takeda Pharmaceutical Company; Advisory Board: Abbott Laboratories, Access Health, AstraZeneca Pharmaceuticals, Atherogenics, Daiichi-Sankyo, Inc., Kinemed, Merck & Co., Inc., Merck/Schering-Plough, Oscient Pharmaceuticals, Pfizer
Laboratories, PreEmptive Meds, Roche Pharmaceuticals, Takeda Pharmaceutical Company, Xinthria Pharmaceuticals; Equity/Board of Directors: Angiogen, Professional Evaluation, Inc. Medical Education Company, Sonogene, Xinthria Pharmaceuticals
Peter H. Jones, MD
Disclosure: Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals, Pfizer Laboratories; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Merck Schering/Plough, Pfizer Laboratories
Daniel J. Rader, MD
Disclosure: Grant/Research Support: AstraZeneca Pharmaceuticals, Boehringer Ingelheim Corporation, Bristol-Myers Squibb Company, Bruin Pharmaceuticals, GlaxoSmithKline, KOS Pharmaceuticals, Merck & Co. Inc., Pfizer Laboratories, Schering-Plough Corporation, Takeda Pharmaceutical Company; Consultant: Abbott Laboratories, AstraZeneca Pharmaceuticals,
Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline, Johnson & Johnson, KOS Pharmaceuticals, Merck & Co. Inc., Merck/Schering-Plough, Pfizer Laboratories, Resverlogix Corp., sanofi-aventis U.S. LLC., Schering-Plough Corporation, Takeda Pharmaceutical Company, Wyeth; Speakers' Bureau: Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Johnson & Johnson, KOS Pharmaceuticals, Merck
& Co. Inc., Merck/Schering-Plough, Pfizer Laboratories, sanofi-aventis U.S. LLC, Schering-Plough Corporation, Takeda Pharmaceutical Company, Wyeth
|
 |
Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for Physicians.
Temple University School of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
